LAMair™

Overview

Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease that primarily affects women of reproductive age and can lead to pneumothorax, chylous effusions, and declining lung function.¹ While high-resolution CT (HRCT) remains the cornerstone of evaluation, many individuals lack definitive radiographic or extrapulmonary features, resulting in diagnostic uncertainty and delayed clinical clarity.2

Vascular Endothelial Growth Factor-D (VEGF-D) has emerged as a meaningful biomarker associated with the lymphatic involvement characteristic of LAM.3 When considered alongside HRCT findings and the broader clinical context, elevated VEGF-D levels can enhance diagnostic confidence and may help reduce the need for invasive procedures such as lung biopsy.4 Studies also indicate that VEGF-D levels may reflect aspects of disease burden and can decrease with mTOR inhibitor therapy, providing supplemental insight during clinical follow-up.5

TrilliumBiO’s VEGF-D* assay offers a quantitative serum measurement to support clinicians in the evaluation and ongoing management of individuals with suspected LAM.

Clinical Utility

Enhanced Diagnostic Confidence

  • VEGF-D provides important biological context for suspected LAM. When interpreted with HRCT, elevated values can increase diagnostic certainty in individuals whose imaging or clinical features are atypical or incomplete.4

Differentiation From Other Cystic Lung Diseases

  • VEGF-D is commonly elevated in LAM but typically remains within reference ranges in conditions such as Birt–Hogg–Dubé syndrome, pulmonary langerhans cell histiocytosis (PLCH), lymphocytic interstitial pneumonia (LIP), and emphysema, helping refine diagnostic considerations.5

Insight Into Disease Burden

  • Higher VEGF-D concentrations have been associated with increased lymphatic involvement and certain measures of physiological impairment, supporting a more comprehensive baseline assessment.5

Support for Longitudinal Assessment

  • VEGF-D may decrease following initiation of mTOR inhibitor therapy, offering an additional data point for clinicians when monitoring disease trajectory over time.5

Understanding LAM – key research and patient stories

Provider Test Kit Request Form

All fields required unless otherwise noted.
The NPI number of the authorizing physician is required to order the test.
Name

Your Order

Please select the quantity you would like to order:
Contact Request
Agreement Review

*These assays were developed and their performance characteristics determined by TrilliumBiO. They have not been cleared or approved by the U.S. Food and Drug Administration.

1. McCormack FX, Gupta N, Finlay GR, et al. Lymphangioleiomyomatosis: A Clinical Update. Chest. 2016;150(5):1023–1032. 2. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis Diagnosis and Management: Executive Summary of the 2016 ATS/JRS Clinical Practice Guideline. Am J Respir Crit Care Med. 2017;196(10):1337–1348. 3. Young LR, Inoue Y, McCormack FX. Diagnostic Potential of Serum VEGF-D in Lymphangioleiomyomatosis. N Engl J Med. 2008;358:199–200. 4. Young LR, Lee HS, Inoue Y, et al. Serum VEGF-D: A Diagnostic and Prognostic Biomarker for LAM. Am J Respir Crit Care Med. 2013;187(7):797–805. 5. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in VEGF-D Levels Reflect Lymphatic Involvement and Response to Sirolimus in Lymphangioleiomyomatosis. Chest. 2010;137(5):1071–1077. 6. Moss J, Taveira-DaSilva AM, Seaman L, et al. Normal VEGF-D Levels in a Subset of Patients with Confirmed LAM. Chest. 2010;137(5):1058–1065.